Oncology Molecular Diagnostics Market Research Explores Growth Within A $10.13 Billion Opportunity

The oncology molecular diagnostics market is on track for substantial growth as advancements in technology and personalized medicine continue to drive demand. With new innovations improving cancer detection and treatment, this sector is rapidly evolving and opening new opportunities worldwide. Let's explore the market's expected expansion, key players, emerging trends, and major segments shaping its future.

Projected Growth and Market Size of the Oncology Molecular Diagnostics Market
The oncology molecular diagnostics market is forecasted to experience significant expansion, reaching a value of $10.13 billion by the year 2030. This growth is expected at an impressive compound annual growth rate (CAGR) of 12.4%. Factors contributing to this rapid increase include the broader adoption of precision oncology techniques, innovations in liquid biopsy technology, greater demand for personalized cancer therapies, implementation of AI-driven data analysis, and deeper penetration into emerging markets. Key trends shaping the market's progression involve the rise of companion diagnostics, expanded use of liquid biopsies, growth in biomarker-based testing, enhanced cancer screening initiatives, and an overall push for early and accurate cancer identification.

Download a free sample of the Oncology Molecular Diagnostics market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3457&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Leading Organizations Influencing the Oncology Molecular Diagnostics Market
Several major corporations dominate the oncology molecular diagnostics landscape, including F. Hoffmann-La Roche AG, Bayer AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthcare AG, Becton dic*kinson and Company, Agilent Technologies Inc., HTG Molecular Diagnostics Inc., Hologic Inc., Illumina Inc., bioMérieux SA, Beckman Coulter Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corp., Bio-Techne Corporation, OPKO Health Inc., Myriad Genetics Inc., Guardant Health AMEA, Veracyte Inc., Adaptive Biotechnologies Corp., Foundation Medicine Inc., Pacific Biosciences of California Inc., NanoString Technologies Inc., and Genomic Health Inc.
In a strategic move, Singapore-based INEX Innovate Pte Ltd acquired Taiwan's Yourgene Health in June 2023, aiming to bolster its capabilities in fetal health, oncology R&D, and bioinformatics. Yourgene Health, a genomics-focused molecular diagnostics entity, is expanding its genetic testing portfolio to include oncology applications, enhancing INEX Innovate's presence in this field.

Emerging Trends Driving the Oncology Molecular Diagnostics Market Worldwide
Companies within this market are increasingly investing in cutting-edge genomics technologies such as next-generation cancer genome sequencing, computational analytics, and novel tumor modeling methods. These innovations help improve early cancer detection, precise mutation identification, and tailored treatment strategies. Such advancements not only boost diagnostic accuracy but also shorten turnaround times, addressing the demand for localized and highly precise molecular testing.
For example, in May 2024, OncoHelix-CoLab, a Canadian precision oncology company specializing in genomic and immune profiling, launched a state-of-the-art laboratory at Burjeel Medical City in the UAE. This facility, developed through a partnership with Burjeel Holdings, enhances regional diagnostic capabilities by allowing complex molecular and immunology tests to be performed locally instead of overseas. Among its specialized offerings is advanced testing for several cancers like prostate cancer, supported by collaborations such as the one with Nanostics for the ClarityDX Prostate assay.

View the full Oncology Molecular Diagnostics market report:
https://www.thebusinessresearchcompany.com/report/oncology-molecular-diagnostics-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Dominant Market Segments within Oncology Molecular Diagnostics
The oncology molecular diagnostics market can be categorized into several key segments:
1) By Product: Instruments, Reagents, and Other Products
2) By Technology: Polymerase Chain Reaction (PCR), In-Situ Hybridization (ISH), Isothermic Nucleic Acid Amplification Technology (INNAT), Chips and Microarrays, Sequencing, Mass Spectroscopy, Transcription Mediated Amplification (TMA), and Other Technologies
3) By End User: Hospitals, Diagnostic Centers, Academic and Research Institutes, and Other End Users

Detailed subcategories include:
- Instruments such as PCR machines, sequencers, microarray platforms, and FISH instruments
- Reagents like DNA and RNA extraction kits, PCR reagents and kits, next-generation sequencing (NGS) library preparation kits, and diagnostic assay reagents
- Other Products encompassing software for data analysis and interpretation, quality control and calibration materials, consumables for molecular testing, and oncology biomarkers

This segmentation offers a comprehensive framework that supports the ongoing growth and specialization of the oncology molecular diagnostics market.

Our 2026 reports feature deeper market intelligence with market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.